medigraphic.com
ISSN 0138-7103 (Print)

2016, Number 1

<< Back Next >>

Revista del Hospital Psiquiátrico de La Habana 2016; 13 (1)

Efficacy of new anticonvulsants as modulators of affection in the Age Bipolar

Pedrosa PD, Torres LJL, Pedrosa PL, Pedrosa OTL

Language: Spanish
References: 85
Page:
PDF size: 160.78 Kb.


ABSTRACT

Introduction: Bipolar disorder is a serious mental illness, chronic, phasic, recurrent and disabling course, hence the importance in a timely therapeutic drug that regardless having different mechanisms of action, combination with the lowest possible risk of interactions and adverse effects in this pharmacological arsenal appear with the term "mood stabilizers".
Objective: To address from a literature review current considerations regarding the efficacy of new molecules anticonvulsants in bipolar disease.
Method: Thematic review based on the literature, which has current and relevant information regardless of the year of publication. The search was conducted in the databases: Intramed, Pubmed, Google Scholar, Cochrane, and Medline, selected descriptors in Spanish, English and French.
Development: The Pan American Health Organization has declared epidemic affective disorders, for the scientific environment this evidence is a challenging point height and therefore urges early diagnosis and appropriate drug therapy. As it has not been possible to develop an ideal mood stabilizer drug, it has led researchers to develop alternative treatments with antiepileptic agents, regardless their mechanism of action has not been well established have demonstrated potent efficacy in the treatment of bipolar disorder.
Conclusions: The anticonvulsant mood stabilizers demonstrate their effectiveness as agents for their safety profile and drug interactions, good tolerance, relative scarcity of relevant adverse effects and ease of administration that require less need for monitoring.


REFERENCES

  1. Grupo de Trabajo de la Guía de Práctica Clínica sobre Trastorno Bipolar. Guía de práctica Clínica sobre Trastorno Bipolar. Madrid: Plan de Calidad para el Sistema Nacional de salud del Ministerio de sanidad, Servicios Sociales e Igualdad. Universidad de Alcalá. Asociación Española de Neuropsiquiatría. 2012. UAH/AEN Núm. 2012

  2. 2.UpToDate (Firm). UpToDate online [Internet]. 2001. [citado 2 Sep 2015]. Disponible en: http://www.uptodate.com/online

  3. Monczor M. Tratamiento a largo plazo del trastorno bipolar. ¿Existe evidencia clínica suficiente? En: Moizes Zowicz J, editor. Psicofarmacología Psicodinámica IV: Actualizaciones 2003. 1a ed. Buenos Aires; 2004. p. 145-60.

  4. Crespo JM. Anticomicials en NP: el seus usos més enllá de l´epilépsia. [ Internet]. [Citado 20 Ago 2015 ].Disponible en: http//www.acmcb.es/files/425-316- documento/Jos%C3.%A9M.Crespo.pdf&prev=search.

  5. Vazquez GH, Nasetta S, Mercado B, Romero E, et al. Validation of the TEMP S-A Buenos Aires: Spanish psychometric validation of affective temperaments in a population study of Argentina. J Affect Disord. 2007;100(1-3):23–9.

  6. Chengappa KNR, Levine J. El uso de los nuevos anticonvulsivantes en los trastornos bipolares. En: Vieta E, editor. Trastornos bipolares. Avances clínicos y terapéuticos. Madrid: Ed. Medica Panamericana; 2001. p. 1-15.

  7. Lambert PA, Carraz G, Borselli S. Action neuro-psychotrope d’un nouvel anti-epileptiche: le Depamide. Ann Med Psychol (Paris). 1966;124(5):707-10.

  8. Okuma T, Kishimoto A, Inoue K. Anti-manic and prophylactic effects of carbamazepine(Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiatr Neurol Jpn. 1973;27(4):283-97.

  9. Chengappa KN, Rathore D, Levine J. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord. 1999;1(1):42-53.

  10. Post RM, Uhde TW. Treatment of mood disorders with antiepileptic medications: clinical and theoretical implications. Epilepsia. 1983;24(suppl 2):97-108.

  11. Pérez Camacho MD. Nuevos eutimizantes en los trastornos bipolares (segunda parte).Icapsi Comunication. [Citado 12 Ago 2015]. Disponible en: http://icapsi.blogspot.com/2010/03/nuevos-eutimizantes-en-los-trastornos15.html.

  12. Ghaemi SN, Gaughan S. Novel anticonvulsants: a new generation of mood stabilizers?. Harv Rev Psychiatry. 2000;8(1):1-7.

  13. Stanton SP, Keck Jr. PE, McElroy SL. Treatment of acute mania with gabapentin. Am J Psychiatry. 1997;154(2):287.

  14. 14.Perugi G, Toni C, Ruffolo G, Sartini S, Simonini E, Akiskal HS. Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. Pharmacopsychiatry 1999;32(4):136-41.

  15. 15.Sussman N. Gabapentina: una nueva opción terapéutica eutimizante. III Congreso Nacional de Psiquiatría. 1998.

  16. 16.Schaffer CB, Schaffer LC. Gabapentin in the treatment of bipolar disorder. Am J Psychiatry. 1997;154(2):291-2.

  17. Sajatovic M, Madhusoodanan S, Coconcea N. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs Aging. 2005; 22(1):39-54.

  18. Dubovsky SL, Buzan RD. Novel alternatives and supplements to lithium and anticonvulsants for bipolar affective disorder. J Clin Psychiatry. 1997; 58(5):224-42.

  19. Hoollander E, Wong CH. Conceptos actuales en el diagnóstico y tratamiento de los trastornos psiquiátricos frecuentes. Segunda edición. Handbooks in Health Care Co; 2007. p. 69, 75, 76, 167.

  20. Domenech J. Aspectos clínicos prácticos del uso de anticomiciales. Actas Esp Psiquiatr. 2008;36(Suppl 3):75-87.

  21. 21.Triple i CENTRAL NERVOUS SYSTEM Prescribing Guide. WINTER/SPRING; 2005. p. 144, 145.

  22. Short C, Cooke L. Hypomania induced by gabapentin. Br J Psychiatry. 1995;166(6):679-80.

  23. McElroy SL, Soutullo CA, Keck PE Jr, Kmetz GF. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann Clin Psychiatry. 1997;99(2):99-103.

  24. Antiepilépticos y anticonvulsivantes. En: Guía práctica de farmacología del sistema nervioso central. Madrid: Ediciones s/n; 2001. p.194-231.

  25. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorders. Neuropsychobiology. 1998;38(3):119-30.

  26. 26.Stahl SM. Newer antidepressants and mood stabilizers. En: Stahl SM, editor. Essential psychopharmacology. 2nd ed. Cambridge: Cambridge University Press; 2000. p. 245-95.

  27. 27.Southam E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol. 1998;358(1):19-24.

  28. Erfurth A, Amann B, Grunze H. Female genital disorder as adverse symptom of lamotrigine treatment. A serotoninergic effect?. Neuropsychobiology. 1998;38(3):200-1.

  29. 29.Shiah IS, Yatham LN, Lam RW, et al. Effects of lamotrigine on the 5-HT1A receptor function in healthy human males. J Affect Disord. 1998;49(2):157-62.

  30. 30.Bentley B, Ascher J, Earl N, Monaghan E, Evonivk G, Batey S, et al. A one year open label study of the safety and efficacy of lamotrigine in the treatment of bipolar depression. Eur Neuropsycopharmacol. 2000;10(Suppl 3):236.

  31. Nolen WA, Bloemkolk D. Opciones terapéuticas en la depresión bipolar. En: Vieta E, editor. Trastornos bipolares. Avances clínicos y terapéuticos. Madrid: Ed. Médica Panamericana; 2001. p. 257-69.

  32. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20(6):607-14.

  33. 33.Calabrese JR, Suppes T, Bowden CL. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatr. 2000;61(11):841-50.

  34. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry. 2000;12(1):5-10.

  35. Wikinski S, Jufe G, editores. El tratamiento Farmacológico en Psiquiatría. Madrid: Ed. Médica Panamericana; 2005. p. 72, 88, 156, 187, 188.

  36. Van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(2):223-31.

  37. 37.Lamictal (lamotrigina). Monografía del producto. Glaxo Wellcome.1999.

  38. 38.Bozikas V, Vartzopoulos D, Phocas C, Karavatos A, Kaprinis G. Lamotrigine-induced rash after sun exposure. Am J Psychiatry. 1999;156(12):2015-6.

  39. 39.Buzan RD, Dubovsky SL. Recurrence of lamotrigine-associated rash with rechallenge. J Clin Psychiatry.1998;59(2):87.

  40. 40.Damiani JT, Christensen RC. Lamotrigine-associated neutropenia in a geriatric patient. Am J Geriatr Psychiatry. 2000;8(4):346.

  41. 41.Solvason HB. Agranulocitosis associated with lamotrigine. Am J Psychiatry. 2000;157(10):1704.

  42. Segarra R, Gutiérrez M, Eguíluz I, Rodríguez M. Lamotrigina en el tratamiento del trastorno afectivo bipolar y del trastorno esquizoafectivo. El papel de los nuevos anticomiciales. Psiquiatr Biol. 2002;9(1):41-4.

  43. Grunze H, Erfurth A, Marcuse A, Amann B, Norman C, Walden J. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatr. 1999;60(11):759-62.

  44. Kauffman KR. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry. 1998;10(4):181-4.

  45. Rodríguez Jiménez R, Ponce G. Uso de antiepilépticos en adicciones. Actas Esp Psiquiatr. 2008;36(Suppl 3):22-27.

  46. 46. Corbella B, Vieta E, Benaberre A. Utilización del topiramato como nuevo estabilizador del humor. Psiquiatr Biol. 2000;7:268-74.

  47. Marcotte D. Use of topiramate, a new antie-pileptic as a mood stabilizer. J Affect Disord.1998;50(2-3): 245-51.

  48. Vieta E, Goikolea JM, Olivares JM.1-year follow-up of patients treated with risperidone and topiramate for a manic episode. J Clin Psychiatry. 2003;64(7):834-9.

  49. 49.Vieta E, Gilabert A, Rodríguez A, García-Castrillón A, Luna MJ, Arrufat E, et al. Effectiveness and safety of topiramate in treatment-resistant bipolar disorder. Actas Esp Psiquiatr. 2001;29(3):148-52.

  50. Barzman DH, DelBello MP, Kowatch RA. Adjunctive topiramate in hospitalized children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol. 2005;15(6):931-7.

  51. Chengappa KNR, Schwarzman LK, Hulihan JF. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry. 2006;67(11):1698-706.

  52. Eutimia.com [Internet]. [citado 12 Ago 2015] . Disponible en: http://www.eutimia.com/psicofarmacos/anticiclicos/topiramato.htm.

  53. Chengappa KNR, Rathore D, Levine J, Atzert R, Solai L, Parepale H, et al. Efectividad y seguridad del topiramato en el trastorno bipolar. [actualizado 19 Jun 2015; citado 12 Ago 2015]. Disponible en: http://www.slideshare.net/valenciamanuel1/nuevos-moduladores-del-afecto&prev=search

  54. Andrade C. Confusion and dysphoria with low-dose topiramate in a patient with bipolar disorder. Bipolar Disord. 2001;3(4):211-2.

  55. Banta JT, Hoffman K, Cevallos E, Greenfield DS. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol. 2001;132(1):112-4.

  56. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition. 2000;16(10):991-6.

  57. Faigle JW, Menge GP. Pharmacokinetic and metabolic features of oxcarbazepine and their clinical significance. Comparison with carbamazepine. Int Clin Psychopharmacol.1990; 5(Suppl 1):73-2.

  58. Dickinson RG, Hooper WD, Pendlebury SC, Moses D, Eadie MJ. Further clinical and pharmacokinetic observations on the new anticonvulsant, oxcarbazepine. Clin Exp Neurol. 1988;25:127-33.

  59. Hummel B, Walden J, Stampfer R. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord. 2002;4(6):412-7.

  60. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(Suppl 4):1–50.

  61. Vieta E, Benabarre A, Sánchez-Moreno J. Nuevos tratamientos: antiepilépticos de última generación. En: Vieta E, editor. Novedades en el Tratamiento del Trastorno Bipolar. 2a ed. Buenos Aires;Madrid: Ed. Médica Panamericana; 2007. p. 36-45.

  62. Vieta E, Colom F, Martinez-Aran A. Los nuevos antiepilépticos en el tratamiento de los trastornos afectivos. Psicofarmacologia.1998;3:7-14.

  63. GAONA V. Neuropediatría.com. 2005. [citado 12 Sep 2015].Disponible en:http://www.neuropediatria.com.py/book/medicamentos /Antiepilepticos/oxcarbacepina.htm

  64. Goldberg JF, Burdick KE. Levetiracetam for acute mania. Am J Psychiatry. 2002; 159(1):148.

  65. Soria CA, Remedi G. Levetiracetam as mood stabilizer in the treatment of pharmacologic hypomania in bipolar II elderly patients. Int J Neuropsychopharmacol. 2002;5(suppl 1):S57.

  66. Grunze H, Langosch J, Born C, et al. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry. 2003:64(7):781-4.

  67. Saíz Díaz RA. Antiepilépticos: Aportación de los nuevos fármacos.

  68. Inf Ter Sist Nac Salud. 2004;28:33-40.

  69. Owen RT. Pregabalin: its efficacy, safety and tolerabi­lity profile in generalized Anxiety. Drugs Today (Barc). 2007;43(9):601-10.

  70. Gelder MG, López-Ibor JJ, Andreasen N, editores. Tratado de psiquiatría, tomo II; 1a ed. Barcelona: Ars Medica; 2003.

  71. Consejo General de Colegios Oficiales de Farmacéuticos. Base de datos del medicamento. [citado 12 Sep 2015] .Disponible en: HTUhttp://www.portalfarma.com/home.nsf

  72. EMEA. Lyrica®. Scientific Discussion. 2004.[citado 12 Sep 2015]. Disponible en: HTUhttp://www.emea.eu.int/humandocs/Huma ns/EPAR/lyrica/lyrica.htm

  73. Anónimo. Pregabalina: somnolencia, dependencia, arritmias, insuficiencia cardíaca. Butlletí groc. 2013;26(2):6-8.

  74. Anónimo. Gabapentine, prégabaline: abus et dépendences. Rev Prescrire. 2012;32 (340):116-8.

  75. 74.INFACA.Scientific Discussion. 2013.[citado12Sep2015].Disponible en: http://www.osakidetza.euskadi.net/contenidos/informacion/ cevime_infac/eu_miez/ adjuntos/INFAC_Vol_21_N_2.pdf

  76. Yatham LN, Kusumakar V, Calabrese JR, Rao R, Scarrow G, Kroeker G. Third generation anticonvulsants in bipolar disorder: a review efficacy and summary of clinical recommendations. J Clin Psychiatry. 2002;63(4):275-83.

  77. Kanba S, Yagi G, Kamijima K, Suzuki T, Tajima O, Otaki J, et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry.1994;18(4):707-15.

  78. Ananda A, Bukhari L, Jennings S. A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. J Clin Psychiatry. 2005; 66(2):195-8.

  79. Ghaemi SN, Zablotsky B, Filkowski MM.An open prospective study of zonisamide in acute bipolar depression.J Clin Psychopharmacol. 2006;26(4):385-8.

  80. Gordon A, Price LH. Mood stabilization and weight loss with topiramate. Am J Psychiatry.1999;156(6):868-9.

  81. López Tricas JM. Antiepilépticos 2da Generación. Prospectiva. [citado 12 Sep 2015]. Disponible en: www.info-farmacia.com.

  82. https://docs.google.com/presentation/d/1x90gHOZMFQnfAnC_dBcLHYv7Yf59hLk0a3ub81DuXQg/embed?hl=es&loop=true&size=s&start=true#slide=id.p33

  83. Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs. 2011;25(2):89-107.

  84. 82.Amann B, Sterr A, Vieta E. An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients. J Clin Psychopharmacol. 2006; 26(5):534-6.

  85. Segal J, Walton S, Clark H, Berk M. Pharmacotherapy of mania: A review. Int J Psychiatry Clin Pract. 2000;4(3):171-93.




2020     |     www.medigraphic.com